FBIO — Fortress Biotech Cashflow Statement
0.000.00%
- $48.44m
- $25.38m
- $57.68m
Annual cashflow statement for Fortress Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -103 | -165 | -214 | -154 | -121 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 20.4 | 6.81 | 27.8 | 32.5 | 44.3 |
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -4.78 | 36.4 | -0.715 | -12.5 | -8.13 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -83.7 | -117 | -179 | -128 | -80.2 |
Capital Expenditures | -3.13 | -4.97 | -2.71 | -5.06 | -15 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -4.04 | 45.5 | -20.2 | 2.96 | 0 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -7.16 | 40.5 | -22.9 | -2.1 | -15 |
Financing Cash Flow Items | 41.5 | 119 | 14.2 | 4.59 | 12.3 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 172 | 149 | 75.3 | 32.7 | 70.6 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 81.6 | 73 | -127 | -97.6 | -24.6 |